ENDRA Life Sciences (NDRA) Asset Writedowns and Impairment (2018 - 2019)
ENDRA Life Sciences' (NDRA) quarterly Asset Writedowns and Impairment came in at $249256.0 in Q4 2019, down 13.31% quarter-over-quarter from $287541.0 in Q3 2018.
Powered by 
Analysis
ENDRA Life Sciences (NDRA) Asset Writedowns and Impairment (2018 - 2019) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Asset Writedowns and Impairment for 2 consecutive years, with $249256.0 the latest figure, recorded in Q4 2019.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $249256.0 in Q4 2019; TTM through Dec 2019 was $536797.0, a 86.69% increase from a year earlier, with the FY2019 full-year figure at $249256.0, down 13.31% from the prior year.
- Asset Writedowns and Impairment was $249256.0 for Q4 2019 at ENDRA Life Sciences, down from $287541.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $287541.0 in Q3 2018 and troughed at $249256.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 28.97 Bn | 27.09 Bn | 2.18 Bn |
| 2 | Lantheus Holdings | 6.56 Bn | 5.97 Bn | 241.86 Mn |
| 3 | Heartflow | 4.40 Bn | 4.03 Bn | 53.19 Mn |
| 4 | Neogen | 2.83 Bn | 2.64 Bn | 107.80 Mn |
| 5 | Butterfly Network | 1.88 Bn | 1.75 Bn | 23.29 Mn |
| 6 | Ceribell | 931.50 Mn | 802.24 Mn | 25.94 Mn |
| 7 | Varex Imaging | 779.32 Mn | 694.02 Mn | 76.70 Mn |
| 8 | Anbio Biotechnology | 755.43 Mn | 743.53 Mn | - |
| 9 | QuidelOrtho | 725.35 Mn | 601.95 Mn | - |
| 10 | ENDRA Life Sciences | 8.25 Mn | 2.71 Mn | - |